The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
Oncgnostics will use MDxHealth's methylation-specific PCR in the GynTect test for cervical cancer, the fourth such test to use the technology.
Asuragen said that that in the second half of this year it will release research-use-only reagents for evaluating FMR1 methylation status in the hopes of obtaining independent validation of the technology.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.